Patents by Inventor Gabriel Lopez-Berestein
Gabriel Lopez-Berestein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
BCR-ABL directed compositions and uses for inhibiting Philadelphia chromesome stimulated cell growth
Patent number: 6537804Abstract: The present invention provides methods for detecting and quantitating BCR-ABL gene products and other abnormal ABL gene products of Ph1-positive leukemic cells. The invention further provides methods for determining the relative number of leukemic cells compared with normal ABL cells to assess the tumor burden of a patient. In another aspect, the methods of the present invention can be used to determine a specific phase of leukemia, particularly chronic-phase CML.Type: GrantFiled: June 21, 1999Date of Patent: March 25, 2003Assignee: Board of Regents, The University of Texas SystemsInventors: Ralph B. Arlinghaus, Jiaxin Liu, Gabriel Lopez-Berestein, Dai Lu, Yun Wu -
Publication number: 20030012812Abstract: The present invention provides novel compositions and methods for use in the treatment of Bcl-2-associated diseases like cancer, specifically, in the treatment of follicular lymphoma (FL). The compositions contain antisense oligonucleotides that hybridize to Bcl-2 nucleic acids, the gene products of which are known to interact with the tumorigenic protein Bcl-2. Used alone, or in conjunction with other antisense oligonucleotides, these compositions inhibit the proliferation of FL cancer cells.Type: ApplicationFiled: October 4, 1996Publication date: January 16, 2003Inventors: MAR TORMO, ANA M. TARI, GABRIEL LOPEZ-BERESTEIN
-
Publication number: 20020143062Abstract: Disclosed herein are simple and unique methods of methods of preparing liposomal compositions of N-(4-hydroxyphenyl) retinamide (4HPR) and/or other retinoids. Also disclosed are liposomal 4HPR compositions prepared by such methods, and use of such compositions in the treatment of diseases, such as breast cancer. This invention further provides methods for improving the efficacy of N-(4-hydroxyphenyl) retinamide (4HPR) as a chemopreventive agent in the presence of agents that potentiates its ability increase the expression of inducible nitric oxide synthase (iNOS, and NO production in cells.Type: ApplicationFiled: October 17, 2001Publication date: October 3, 2002Applicant: Board of Regents, The University of Texas SystemInventors: Gabriel Lopez-Berestein, Ana M. Tari, Soo-Jeong Lim
-
Patent number: 6200597Abstract: A reduced-toxicity formulation of carotenoids is disclosed which is stable in an aqueous environment. The formulation includes a carotenoid, lipid arrier particles (such as liposomes), and an intercalation promoter agent (such as a triglyceride), which causes the carotenoid to be substantially uniformly distributed with the lipid in the lipid carrier particles. The molar ratio of carotenoid to lipid is greater than about 1:10. Also disclosed is a method of inhibiting the growth of cancer cells, which comprises administering to a living subject a therapeutically effective amount of a composition as described above.Type: GrantFiled: June 10, 1998Date of Patent: March 13, 2001Assignees: Board of Regents, The University of Texas System, Aronex Pharmaceuticals, Inc.Inventors: Kapil Mehta, Roman Perez-Soler, Gabriel Lopez-Berestein, Robert Lenk, Alan C. Hayman
-
Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
Patent number: 6107457Abstract: Compositions comprising a mixture of peptides that bind to molecules involved in Bcr-Abl oncoprotein function are disclosed. In addition, expression of functional BCR protein (p160 BCR) or amino terminal fragments thereof (159, 221 and 413 amino terminal residues) by way of retrovirus vectors will oppose the biological function of Bcr-Abl (p160 BCR) or inactivate Bcr-Abl tyrosine kinase function or its signal transduction function. Bcr and Abl peptides, either tyrosine phosphorylated or unphosphorylated, that bind to a region near the amino terminus of Bcr to prevent formation of tetramer Bcr-Abl molecules, that bind to the SH2 domain of Grb2, to sites on tyrosine phosphorylated Shc protein, to sites of Crkl, and to an SH2 domain of Ras Gap comprise particular peptide preparations of the invention.Type: GrantFiled: February 16, 1995Date of Patent: August 22, 2000Assignee: Board of Regents, The University of Texas SystemInventors: Ralph B. Arlinghaus, Jiaxin Liu, Dai Lu, Gabriel Lopez-Berestein -
Patent number: 6042846Abstract: An improved delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is selected from the group consisting of phosphodiester oligonucleotides, phosphorothioate oligonucleotides, and p-ethoxy oligonucleotides.Type: GrantFiled: July 9, 1998Date of Patent: March 28, 2000Assignee: Board of Regents, University of Texas SystemInventors: Gabriel Lopez-Berestein, Ana Maria Tari
-
Patent number: 5968737Abstract: Complementary DNA and genomic clones for three variants of GST-.pi. are disclosed. It is demonstrated that certain of these variants are overexpressed in gliomas, thereby indicating an involvement with that form of cancer. This permits the detection and treatment of certain classes of tumors using new compositions such as GST-.pi. genes, oligonucleotides, peptides and antibodies.Type: GrantFiled: November 12, 1996Date of Patent: October 19, 1999Assignees: The University of Mississippi, The Board of Regents, The University of Texas SystemInventors: Francis Ali-Osman, Gabriel Lopez-Berestein, John K. Buolamwini, Gamil Antoun, Hui-Wen Lo, Charles Keller, Olanike Akande
-
Patent number: 5965158Abstract: A method is disclosed for preparing a stable preliposomal powder which, when reconstituted with water or saline solution, forms a suspension of liposomes containing a polyene drug, such as nystatin. The method involves the steps of combining at least one phospholipid with a first organic solvent to form a first solution, adding a clarifying amount of water to the first solution, combining a polyene with a second organic solvent to form a second solution, combining the first and second solutions to produce a substantially clear combined solution, and then removing the organic solvents, leaving a powder.Type: GrantFiled: November 26, 1997Date of Patent: October 12, 1999Assignees: The University of Texas System & Board of Regents, Aronex Pharmaceuticals, Inc.Inventors: Robert P. Link, Reeta Mehta, Gabriel Lopez-Berestein
-
Patent number: 5855911Abstract: An improved delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is selected from the group consisting of phosphodiester oligonucleotides, phosphorothioate oligonucleotides, and p-ethoxy oligonucleotides.Type: GrantFiled: August 29, 1995Date of Patent: January 5, 1999Assignee: Board of Regents, the University of Texas SystemInventors: Gabriel Lopez-Berestein, Ana Maria Tari
-
Patent number: 5830498Abstract: A method is disclosed for preparing a stable preliposomal powder which, when reconstituted with water or saline solution, forms a suspension of liposomes containing a polyene drug, such as nystatin. The method involves the steps of combining at least one phospholipid with a first organic solvent to form a first solution, adding a clarifying amount of water to the first solution, combining a polyene with a second organic solvent to form a second solution, combining the first and second solutions to produce a substantially clear combined solution, and then removing the organic solvents, leaving a powder.Type: GrantFiled: September 28, 1995Date of Patent: November 3, 1998Assignees: Board of Regents, The University of Texas System, Aronex Pharmaceuticals, Inc.Inventors: Robert P. Lenk, Reeta Mehta, Gabriel Lopez-Berestein
-
Patent number: 5811119Abstract: A reduced-toxicity formulation of carotenoids is disclosed which is stable in an aqueous environment. The formulation includes a carotenoid, lipid carrier particles (such as liposomes), and an intercalation promoter agent (such as a triglyceride), which causes the carotenoid to be substantially uniformly distributed with the lipid in the lipid carrier particles. The molar ratio of carotenoid to lipid is greater than about 1:10. Also disclosed is a method of inhibiting the growth of cancer cells, which comprises administering to a living subject a therapeutically effective amount of a composition as described above.Type: GrantFiled: October 22, 1996Date of Patent: September 22, 1998Assignees: Board of Regents, the University of Texas, Aronex Pharmaceuticals, Inc.Inventors: Kapil Mehta, Roman Perez-Soler, Gabriel Lopez-Berestein, Robert P. Lenk, Alan C. Hayman, deceased
-
Patent number: 5417978Abstract: A liposomal methyl phosphonate oligonucleotide composition useful in treatment of chronic myeloid leukemia comprises (a) a liposome which comprises at least one phospholipid, and (b) an antisense methyl phosphonate oligonucleotide which is entrapped in the liposome. The molar ratio of phospholipid in the liposome to the methyl phosphonate entrapped in the liposome is between about 100:1 and about 10,000:1. A process for making the composition includes the steps of (a) mixing an antisense methyl phosphonate oligonucleotide in a first organic solvent with at least one phospholipid in a second organic solvent, where the molar ratio of phospholipid to methyl phosphonate is between about 100:1 and about 10,000:1, (b) lyophilizing the mixture formed in step (a), producing a lyophilized powder, (c) hydrating the lyophilized powder, and (d) sonicating the hydrated material.Type: GrantFiled: July 29, 1993Date of Patent: May 23, 1995Assignee: Board of Regents, The University of Texas SystemInventors: Ana Maria Tari, Gabriel Lopez-Berestein, Albert B. Deisseroth
-
Patent number: 5213970Abstract: Disclosed herein is a novel antitumor factor, termed Human Monocyte Toxin, obtained by the precise activation of cells of monocyte/macrophage lineage. Monocytes are isolated in the absence of endotoxin by counterflow elutriation. HMT release can be triggered by exposure to low levels of 6-0-stearoyl muramyl dipeptide, lipopolysaccharide, phorbol myristate acetate or other known macrophage activating agents. Triggering results in the rapid release of HMT which requires transcription, translation, and intact secretory apparatus. The requirement for precise control of the triggering agent concentration is disclosed.The government may have certain rights in the present invention pursuant to NIH grant BRSG 5511.Type: GrantFiled: January 23, 1987Date of Patent: May 25, 1993Assignee: Board of Regents, The University of Texas SystemInventors: Gabriel Lopez-Berestein, Jim Klostergaard, Jim Turpin
-
Patent number: 5198428Abstract: This invention provides a cytotoxin composition that inhibits mitochondrial respiration and causes cytostasis in cells, independent of nitric oxide. The invention comprises a conditioned supernatant derived from macrophage cell line (EA13.5) that inhibits mitochondrial respiration and causes cytostasis in cells. More particularly, the invention comprises a macrophage cytotoxin obtained from conditioned supernatant collected from cultured EA13.5 cell. This macrophage cytotoxin (1) inhibits mitochondrial respiration, (2) causes cytostasis independent of L-arginine derived nitric oxide, (3) is a weakly acidic (pI of about 7.5 to 8.0) glycoprotein (as determined by binding to lentil lectin sepharose). The invention also discloses a method for producing an L-arginine-derived nitric oxide-independent macrophage cytotoxin by culturing EA13.5 cells, adding IFN-.gamma.Type: GrantFiled: April 5, 1991Date of Patent: March 30, 1993Assignee: Board of Regents, The Univ. of Texas SystemInventors: Mathoor Sivaramakrishnan, Stanley D. Tucker, Jim Klostergaard, Gabriel Lopez-Berestein
-
Patent number: 5186940Abstract: The present invention involves the synthesis and use of new platinum compounds. These new platinum compounds are easy to encapsulate in liposomes at high efficiencies. They are further characterized as platinum (II) four coordinate complex having the formula: ##STR1## wherein R.sub.1 and R.sub.2 are carboxylato monoanions bearing a hydrophobic radical function or a single carboxylato dianion bearing a hydrophobic radical function and R.sub.3 is a vicinal diaminoalkane or vicinal diaminocycloalkane. The complex is substantially soluble in methanol or chloroform and substantially insoluble in water. Said complex may be incorporated into phospholipid liposomes. Such platinum complexes encapsulated in phospholipid liposomes are useful for chemotherapy of platinum complex-sensitive tumors.Type: GrantFiled: May 31, 1991Date of Patent: February 16, 1993Assignee: The Board of Regents, The University of Texas SystemInventors: Abdul R. Khokhar, Gabriel Lopez-Berestein, Roman Perez-Soler
-
Patent number: 5178875Abstract: A method is disclosed for preparing a stable preliposomal powder which, when reconstituted with water or saline solution, forms a suspension of liposomes containing a polyene drug, such as nystatin. The method involves the steps of combining at least one phospholipid with a first organic solvent to form a first solution, adding a clarifying amount of water to the first solution, combining a polyene with a second organic solvent to form a second solution, combining the first and second solutions to produce a substantially clear combined solution, and then removing the organic solvents, leaving a powder.Type: GrantFiled: January 14, 1991Date of Patent: January 12, 1993Assignee: The Board of Regents, The University of Texas SystemInventors: Robert P. Lenk, Reeta Mehta, Gabriel Lopez-Berestein
-
Patent number: 5178876Abstract: The present invention involves the synthesis and use of new platinum compounds. These new platinum compounds are easy to encapsulate in liposomes at high efficiencies. They are further characterized as platinum (II) four coordinate complex having the formula: ##STR1## wherein R.sub.1 and R.sub.2 are carboxylato monoanions bearing a hydrophobic radical function or a single carboxylato dianion bearing a hydrophobic radical function and R.sub.3 is a vicinal diaminoalkane or vicinal diaminocycloalkane. The complex is substantially soluble in methanol or chloroform and substantially insoluble in water. Said complex may be incorporated into phospholipid liposomes. Such platinum complexes encapsulated in phospholipid liposomes are useful for chemotherapy of platinum complex-sensitive tumors.Type: GrantFiled: May 31, 1991Date of Patent: January 12, 1993Assignee: The Board of Regents, The University of Texas SystemInventors: Abdul R. Khokhar, Gabriel Lopez-Berestein, Roman Perez-Soler
-
Patent number: 5117022Abstract: The present invention concerns a platinum (II) four-coordinant complex having the formula: ##STR1## wherein R.sub.1 is an alkyl diamine or cycloalkyl diamine and R.sub.2 and R.sub.3 are an alkylcarboxylato containing from five to ten carbon atoms. The R.sub.1 is preferably trans-D,L-1,2-diaminocyclohexane, trans-R,R-1,2-diaminocyclohexane, trans-S,S-1,2-diaminocyclohexane, cis-1,2-diaminocyclohexane ethylene diamine or 1,1-bis(aminomethyl)cyclohexane. The R.sub.2 and R.sub.3 are preferably neohexanoato, neoheptanoato, neononanoato, neodecanoato, neooctanoato, neopentanoato, 2-ethylhexanoato, 2-ehtylbutyrato, 2-propylpropanoato, 2-methyl-2-ethylheptanoato, 2,2-diethylhexanoato, 2,2-dimethyl-4-ethylhexanoato, 2,2-diethyl-4-methylpentanoato, 2,2-dimethyloctanoato, 2-methyl-2-ethylheptanoato, 2,2-diethylhexanoato, 2,2-diethyl-4-methylpentanoato or 2,2,4,4-tetramethylpentanoato.Type: GrantFiled: August 22, 1988Date of Patent: May 26, 1992Assignee: The Board of Regents, The University of Texas SystemInventors: Abdul R. Khokhar, Gabriel Lopez-Berestein, Roman Perez-Soler
-
Patent number: 5041581Abstract: The present invention involves the synthesis and use of new platinum compounds. These new platinum compounds are easy to encapsulate in liposomes at high efficiencies. They are further characterized as platinum (II) four coordinate complex having the formula: ##STR1## wherein R.sub.1 and R.sub.2 are carboxylato monoanions bearing a hydrophobic radical function or a single carboxylato dianion bearing a hydrophobic radical function and R.sub.3 is a vicinal diaminoalkane or vicinal diaminocycloalkane. The complex is substantially soluble in methanol or chloroform and substantially insoluble in water. Said complex may be incorporated into phospholipid liposomes. Such platinum complexes encapsulated in phospholipid liposomes are useful for chemotherapy of platinum complex-sensitive tumors.Type: GrantFiled: October 7, 1986Date of Patent: August 20, 1991Assignee: The University of Texas System Board of RegentsInventors: Abdul R. Khokhar, Gabriel Lopez-Berestein, Roman Perez-Soler
-
Patent number: 5032404Abstract: The present invention involves a liposomal agent for treating disseminated fungal infection in an animal. This liposomal agent comprises a variety of polymer antifungal compounds, particularly hamycin. These antifungal compounds are encapsulated within a liposome decreasing toxicity. This liposome is preferably a stable multilamellar vesicle. The method of administration is preferably parenteral, but may be oral or topical.Type: GrantFiled: February 23, 1989Date of Patent: July 16, 1991Assignee: Board of Regents, The University of Texas SystemInventors: Gabriel Lopez-Berestein, Reeta Mehta